INTERCHANGEABILITY OF MYOCARDIAL CYTOPROTECTORS IN PATIENTS WITH ISCHEMIC HEART DISEASE. DIFFICULT QUESTIONS –SIMPLE SOLUTIONS

Racionalʹnaâ Farmakoterapiâ v Kardiologii

Zh. M. Sizova¹ 

[1] Первый Московский государственный медицинский университет им. И.М.Сеченова;

关键词: ишемическая болезнь сердца;    хроническая сердечная недостаточность;    стенокардия;    прекондиционирование;    цитопротекция;    триметазидин;    оригинальный препарат;    дженерик;    фармакотерапия;   

DOI  :  10.1234/1819-6446-2013-2-183-187

来源: DOAJ

【 摘 要 】

Indications for myocardial cytoprotector, trimetazidine, in patients with ischemic heart disease are analyzed and justified according to evidence based medicine. Results of a multicenter randomized comparative KARDIOKANON study are discussed in terms of efficacy and tolerability of two variants of the complex 12-week treatment in patients with angina II-III functional class, based on the original and generic drugs. The study showed clinical equivalence of the generic DeprenormR (Canonpharma Production) to the original trimetazidine.

【 授权许可】

Unknown